A novel diagnostic Biosensor for ALK-targeted therapy of non-small cell lung cancer (NSCLC)

Worldwide, lung cancer is the leading cause of cancer-related deaths (20% of total) with NSCLC as the most common type. BIOSTAR aims to market an innovative chip-based biosensor as companion diagnostic (CD) for the detection of the EML4-ALK biomarker as a prerequisite for the selection and the subsequent monitoring of ALK-targeted therapy in NSCLC treatment. Our biosensor will be superior to conventional detection methods by combining high-sensitivity, cost-effectiveness and usability.

Network: Eurostars 2; Call: Eurostars Cut-Off 7; Acronym: BIOSTAR17